- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Tadalafil use fails to improve lung function, quality of life in patients with severe asthma: Study
Iran: Once-daily use of Tadalafil (20 mg) for one month did not affect laboratory and clinical outcomes in patients with severe asthma, according to findings from a randomized clinical trial published in Monaldi Archives for Chest Disease.
Asthma is a chronic respiratory disease that affects over 300 million individuals worldwide. This condition is caused by the reaction of the immune system to allergenic particles and substances, leading to increased inflammation, mucus secretion, hyperresponsiveness of the respiratory tract mucosa, smooth muscle contraction, and difficulty breathing during asthma attacks. The primary objective of asthma treatment is to reduce airway inflammation and reverse bronchoconstriction.
Phosphodiesterase inhibitors increase cyclic guanosine monophosphate and cyclic adenosine monophosphate levels, which have been associated with several anti-inflammatory effects that can help alleviate asthma symptoms. Tadalafil, a selective PDE5 inhibitor, prevents the degradation of cGMP and raises its levels. However, the human studies on the effects of specific phosphodiesterase inhibitors (PDE) on pulmonary function are limited leading to the need for experimental studies.
To fill this knowledge gap, Seyed Hamid Borsi, Air Pollution and Respiratory Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, and colleagues aimed to assess the impact of Tadalafil, a selective phosphodiesterase inhibitor, on asthma severity and lung function in patients with severe asthma.
For this purpose, they conducted a randomized, double-blind clinical trial in 2021 at Imam Khomeini Hospital in Ahvaz, Iran. Forty-four patients with severe asthma were enrolled; they were equally divided into a Tadalafil group and a placebo group. The Tadalafil group received 20 mg/day of Tadalafil, while the placebo group received a placebo at the same dose.
The patients' asthma quality of life questionnaire, spirometry tests, quality of life, and 6-minute walk distance were measured at the study's beginning and one month later.
Key findings of the study:
- There was no statistically significant difference between the Tadalafil group and the placebo group in terms of pulmonary parameters.
- The scores for patients' quality of life and the 6-minute walk test at the end of the study did not show any statistically significant improvement compared to the placebo group.
"The results suggest that administration of a daily dose of Tadalafil (20 mg) for one month in patients with severe asthma had no impact on subclinical or clinical outcomes, such as improvements in 6-minute walk distance, lung volume (FEV1, FVC, FEV1/FVC, FEF25-75), and overall quality of life," the researchers wrote.
"There is a need for further investigation with longer follow-up periods and larger sample sizes to evaluate the clinical and laboratory effects of other phosphodiesterase," they concluded.
The limitations of the study include a small sample size, the inclusion of only severe asthma patients, and short follow-up duration. PDEs may potentially affect mild or moderate asthma cases.
Reference:
Borsi SH, Fakhr Mousavi SAAFM, Dargahi Mal-Amir M, Tavakol H, Raji H. Evaluation of the effectiveness of Tadalafil on improving pulmonary function and asthma severity in severe asthmatic patients: a randomized controlled trial study. Monaldi Arch Chest Dis. 2024 Jan 11. doi: 10.4081/monaldi.2024.2685. Epub ahead of print. PMID: 38213275.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751